WHO ICTRP trial
Atorvastatin neuroprotective effects in glial tumor surgey
IRCT201203039196N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT201203039196N1 |
|---|---|
| Public title | Atorvastatin neuroprotective effects in glial tumor surgey |
| Scientific title | Evaluation of atorvastatin effects on plasma MMP 9 concentration in neurosurgical- induced brain injuries after glial tumor resection |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Countries | Iran (Islamic Republic of) |
| Conditions | Glial tumor. Malignant neoplasm of brain, Brain, unspecified;Malignant neoplasm of brain, Brain, unspecified |
| Interventions | Intervention 1: In atorvastatin (Intervention) group: Atorvastatin, tablet 40 mg, twice daily, one week before surgery and two weeks after the surgery. Intervention 2: In placebo (Control) group: Placebo of atorvastatin, tablet 40 mg, twice… |
| Registration date | Mar 17, 2012 |
| Target size | 44 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: